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PreviewsTaking Two TRAILS
The TNF-related apoptosis-inducing ligand (TRAIL)
has well-described anti-inflammatory effects in mod-
els of autoimmune disease, including experimental
autoimmune encephalomyelitis (EAE). In this issue of
Neuron, Aktas, Smorodchenko, and colleagues pre-
sent evidence that TRAIL exerts anti-inflammatory ef-
fects, but also induces neuronal apoptosis, in EAE.
This report poses the therapeutic challenge of facili-
tating TRAIL expression in the periphery while inhibit-
ing TRAIL in the CNS.
Multiple sclerosis (MS) is an inflammatory demyelinat-
ing disease of the human central nervous system. Our
understanding of MS pathogenesis has increased sig-
nificantly in recent years, and the role of neuronal pa-
thology and neuronal degeneration has emerged as a
major focus of research. While this new emphasis has
put neuroprotection on the drawing board of MS thera-
peutic development, there are several challenges be-
fore us. These include obtaining a better understanding
of the molecular mechanisms of neurodegeneration
and the development of in vivo and/or in vitro models
that mimic neurodegenerative aspects of MS.
Experimental autoimmune encephalomyelitis (EAE), a
well-established model of neuroinflammation, has been
used for more than 75 years to model certain immune
aspects of MS. With realization of the importance of
neurodegeneration in the pathogenesis of neurological
disability in MS, investigators have turned significant
efforts toward the study of neuroprotection in EAE.
Neural damage in MS takes several forms: in the white
matter, one finds transection of axons in actively demy-
elinating MS lesions (Trapp et al., 1998) and slow de-
generation of chronically demyelinated axons. Oligo-
dendrocyte apoptosis is also a prominent feature of a
subset of MS white-matter lesions. Cortical demyelin-
ation is extensive in postmortem MS brains. The corti-
cal pathology of MS includes transection of neurites
and apoptosis of neurons (Peterson et al., 2001).
The challenges faced by researchers studying neuro-
protection in EAE are formidable, as the neural injury
observed in EAE models does not faithfully recapitulate
that described in MS (Bradl and Hohlfeld, 2003; Gold
et al., 2000). Most models fail to exhibit inflammatory
demyelination with relative preservation of axons, and
instead demonstrate necrotic changes of the spinal
subpial white matter, with substantial and equivalent
loss of both myelin and axons. Therefore, while axonal
transection in active MS lesions is clearly secondary to
primary demyelination, this sequence is not conserved
in EAE. Cortical demyelination, a prominent feature of
MS brains, is rarely reported in EAE. Degeneration of
chronically demyelinated axons has been described
only in isolated individual EAE studies and is not rou-
tinely quantified. Therefore, more EAE studies of neuro-
protective strategies focus on the neurobehavioral se-verity of the disease. An obvious primary endpoint of a
potent neuroprotective agent—increased demyelinated
axons—has yet to be reported in any EAE study claim-
ing neuroprotective benefits. Furthermore, only rarely
do studies which concentrate on remyelination provide
rigorous quantitation of remyelinated axons.
Difficulties faced by neuroprotection-oriented EAE
researchers do not end with dissimilar pathologies.
Many studies address the potential roles of cytokines
and growth factors as protective agents, which are pro-
posed either to support integrity of the neuron/axon
unit or to facilitate remyelination. Unexpectedly, these
factors have sometimes exhibited immunoregulatory
properties sufficiently potent that inflammatory demye-
lination was abrogated, making it impossible to discern
whether neuroprotection may have occurred. This type
of confound occurred in studies of insulin-like growth
factor-1 (IGF-1), glial cell growth factor-2 (GGF-2), and
nerve growth factor (NGF) (reviewed in Ransohoff et al.,
2002). More recently, blockers of voltage-gated sodium
channels appeared neuroprotective in EAE, but the
mechanism of action became uncertain when the in-
vestigators themselves showed that such channels are
present on lymphocytes and monocytes (reviewed in
Waxman, 2005).
Aktas, Smorodchenko, and colleagues (Aktas et al.,
2005) nicely address this complexity in this issue of
Neuron. It was evident from the outset that TNF-related
apoptosis-inducing ligand (TRAIL) would affect both
neural and immune cells, with putative opposing ac-
tions in EAE. TRAIL was initially described as a selec-
tive inducer of caspase-mediated apoptosis in trans-
formed cells, acting through a complex series of
signaling and nonsignaling (decoy) receptors. It has
been proposed that TRAIL executes a major pathway
for type I interferon (IFN)-mediated cell death for trans-
formed cells (reviewed in Chawla-Sarkar et al., 2003),
and subsequent work showed that TRAIL induces apo-
ptosis in a variety of nontransformed cells types. On
the one hand, TRAIL would be expected to exert immu-
noregulatory functions, by impairing the function or via-
bility of autoreactive T lymphocytes, the orchestrators
of pathogenesis in EAE (Lunemann et al., 2002). The
authors had previously shown, in fact, that levels of cir-
culating soluble TRAIL predicted a beneficial response
to injections of interferon (IFN)-β, which are widely used
to treat MS patients (Wandinger et al., 2003). Further-
more, patients exhibiting positive treatment responses
to IFN-β showed early and sustained upregulation of
TRAIL mRNA expression, which was transient in pa-
tients who did not experience disease amelioration with
their IFN-β treatments. However, their further studies
uncovered a potential dark side for TRAIL, which was
found to induce apoptosis on human neurons and oli-
godendroglia, which were maintained in slice culture
(Nitsch et al., 2000).
Previous studies showed that peripheral blockade of
TRAIL worsened EAE, consistent with its proposed role
in restraining the activity of autoreactive lymphocytes
(Hilliard et al., 2001). The current study was designed
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356to address whether the potential for neural damage by g
TRAIL would be pertinent for the outcome of EAE. p
In the paper, substantial attention was paid to con- n
trols, to help clarify which effects of TRAIL were exerted i
peripherally (toward the immune aspects of EAE) and s
which were central, and the reported results are there- m
fore persuasive. To block the action of TRAIL, the inves- r
tigators used DR5:Fc, a fusion protein incorporating a t
TRAIL binding domain with an immunoglobulin Fc por- a
tion. This moiety was administered intracisternally, and o
careful studies mapped the distribution of the injected s
reagent. These studies were supplemented with de- a
tailed quantitative analysis of CNS-infiltrating leuko- p
cytes, as well as definition of the functional properties (
(proliferation and cytokine secretion) of autoreactive v
cells from the lymph nodes of immunized mice. Wisely, t
the investigators used control injections of Fc pro- T
tein, in preference to phosphate-buffered saline (PBS), T
which is all-too-commonly employed, but which leaves m
open the question of protein loading and inactivation of (
effector macrophages. Furthermore, littermate knockout a
and wild-type mice were directly compared in studies s
using adoptive transfer of TRAIL−/− lymphocytes, again d
providing a level of control which is frequently scanted t
in EAE studies. r
There are concerns about the relevance of T cell-
mediated neuronal killing in MS cortex. Demyelination R
of the cerebral cortex typically occurs without infiltra- D
tion of hematogenous inflammatory cells and without L
breakdown of the blood-brain barrier (Peterson et al., T
2001) making serum TRAIL an unlikely source for corti- C
cal neuronal killing in MS. Data are mixed on whether
lymphocytes are increased in cortical MS lesions, and
to date, lymphocytes have not been identified next to S
neurons. From the EAE studies, neuronal expression of
ATRAIL receptor appears to be the crucial step in TRAIL-
hmediated killing. This begs the question: Why do neu-
E
rons in EAE brains express death receptors? Are they
Btruly suicidal or is it possible that the TRAIL receptors
7
have additional functions and/or ligands? TRAIL could
C
reach the neuron by several routes but, as shown in S
the current study, only kills neurons expressing TRAIL
G
receptors. Detection of TRAIL receptors on neuronal 8
parikarya in MS brains, therefore, would support the H
potential relevance of the current research report. (
One experiment in the paper compares EAE neurobe- L
havioral severity in mice receiving wild-type as com- K
pared with TRAIL−/− lymphocytes. Although there were N
statistically significant differences in favor of the inves- W
tigators’ hypotheses, the peak extent of disease in re- P
cipients of wild-type cells was barely detectable (mean A
score = 1, which designates a limp tail). Quantitation of R
lymphocyte numbers in the CNS of mice that received m
the wild-type or knockout lymphocytes would have T
aadded confidence in the significance of these results.
Additionally, it would have been appealing to transfer W
ATRAIL protein along with TRAIL−/− lymphocytes as a
Vfollow-up to these studies, to define whether soluble
WTRAIL plus primed lymphocytes could mediate neural
injury as observed in recipients of wild-type lympho-
D
cytes.
There are aspects of genuine novelty in the current
report, which describes a pathway for lymphocyte-
mediated effector function in EAE-associated neurode-eneration, whereas the focus for some years has been
rimarily on macrophage effectors. The clinical perti-
ence of these data remains to be determined, and it
s not easy to envision how to antagonize TRAIL action
electively in the CNS of MS patients. One initial step
ight be to map the distribution of TRAIL and TRAIL
eceptor in MS brain sections. It would be worthwhile
o define levels of soluble TRAIL in CSF of MS patients
nd controls, and evaluate effects of IFN-β treatment
n levels in MS patients. Importantly, the clinical MS
tudy which showed a relation between soluble TRAIL
nd IFN-β efficacy lasted for 1 year (in a disorder that
lays out over decades), and monitored only relapses
whose frequency is dissociated from the most rele-
ant indices of disability). It would be valuable to know
he relationship between IFN-β-mediated induction of
RAIL mRNA, as well as circulating and CSF levels of
RAIL protein, with disability or neurodegeneration
easures such as expanded disability status scale
EDSS), multiple sclerosis functional composite (MSFC),
nd brain atrophy. For the present, the current report
hows unambiguously how a single molecule can exert
ivergent functions in the immune and nervous sys-
ems during the increasingly complex process of neu-
oinflammation.
ichard M. Ransohoff and Bruce D. Trapp
epartment of Neurosciences
erner Research Institute
he Cleveland Clinic Foundation
leveland, Ohio 44195
elected Reading
ktas, O., Smorodchenko, A., Brocke, S., Infante-Duarte, C., Topp-
off, U.S., Vogt, J., Prozorovski, T., Meier, S., Osmanova, V., Pohl,
., et al. (2005). Neuron 46, this issue, 421–432.
radl, M., and Hohlfeld, R. (2003). J. Neurol. Neurosurg. Psychiatry
4, 1364–1370.
hawla-Sarkar, M., Lindner, D.J., Liu, Y.F., Williams, B.R., Sen, G.C.,
ilverman, R.H., and Borden, E.C. (2003). Apoptosis 8, 237–249.
old, R., Hartung, H.P., and Toyka, K.V. (2000). Mol. Med. Today 6,
8–91.
illiard, B., Wilmen, A., Seidel, C., Liu, T.S., Goke, R., and Chen, Y.
2001). J. Immunol. 166, 1314–1319.
unemann, J.D., Waiczies, S., Ehrlich, S., Wendling, U., Seeger, B.,
amradt, T., and Zipp, F. (2002). J. Immunol. 168, 4881–4888.
itsch, R., Bechmann, I., Deisz, R.A., Haas, D., Lehmann, T.N.,
endling, U., and Zipp, F. (2000). Lancet 356, 827–828.
eterson, J.W., Bo, L., Mork, S., Chang, A., and Trapp, B.D. (2001).
nn. Neurol. 50, 389–400.
ansohoff, R.M., Howe, C.L., and Rodriguez, M. (2002). Trends Im-
unol. 23, 512–516.
rapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mork, S.,
nd Bo, L. (1998). N. Engl. J. Med. 338, 278–285.
andinger, K.P., Lunemann, J.D., Wengert, O., Bellmann-Strobl, J.,
ktas, O., Weber, A., Grundstrom, E., Ehrlich, S., Wernecke, K.D.,
olk, H.D., and Zipp, F. (2003). Lancet 361, 2036–2043.
axman, S.G. (2005). Brain 128, 5–6.
OI 10.1016/j.neuron.2005.04.028
